B. Riley Research Analysts Lift Earnings Estimates for VRDN

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – B. Riley upped their Q2 2025 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. B. Riley analyst K. Patel n…

Read Full Article →